How Cancer therapy Works

Surgical removal of cancerous tissue is the oldest form of cancer treatment, dating back thousands of years. When a tumor is localized and accessible, a surgeon can physically excise it along with a margin of surrounding healthy tissue to ensure no cancer cells remain. This approach works best when the cancer hasn't metastasized—spread to distant parts of the body—because once cancer cells travel through blood or lymph vessels to establish new tumors elsewhere, surgery alone cannot address all disease sites.

Modern cancer surgery often combines multiple techniques to maximize tumor removal while preserving function. Surgeons may use image-guided navigation systems that overlay CT or MRI scans onto the surgical field in real-time, essentially giving them a three-dimensional map to distinguish tumor from healthy tissue. In some cases, surgeons perform "debulking" procedures that remove as much tumor mass as possible even when complete excision isn't feasible, reducing the burden on subsequent treatments like chemotherapy.

The effectiveness of surgical excision depends critically on achieving "clear margins"—confirming under a microscope that the outer edges of removed tissue contain no cancer cells. Pathologists examine tissue samples during and after surgery to guide the surgeon's decisions. If margins test positive for cancer cells, additional surgery or other treatments may be necessary to prevent recurrence from cells left behind.

Radiation therapy uses high-energy photons or particles to damage the DNA inside cancer cells, preventing them from dividing and ultimately causing their death. When radiation strikes a cell, it either breaks DNA strands directly or creates reactive oxygen molecules that attack the DNA indirectly. Cancer cells are particularly vulnerable because they divide rapidly and often have defective DNA repair mechanisms—the same mutations that made them cancerous also make them less able to fix radiation damage.

Modern radiation oncology has evolved from crude whole-body exposure to precision-targeted beams. Techniques like intensity-modulated radiation therapy (IMRT) use computer-controlled machines that shape radiation beams to conform exactly to a tumor's three-dimensional contour, delivering maximum dose to cancer while sparing surrounding organs. Stereotactic body radiotherapy takes this further, delivering ablative doses in just a few sessions by attacking the tumor from dozens of angles, each beam weak individually but collectively devastating where they converge.

The challenge lies in the fact that healthy cells also sustain radiation damage. Treatment is typically fractionated—divided into many small daily doses over several weeks—because normal cells generally repair DNA damage better than cancer cells between sessions. This differential recovery allows radiation to progressively kill cancer while healthy tissue survives, though side effects like fatigue, skin changes, and organ-specific damage still occur depending on what lies in the radiation field.

Chemotherapy uses toxic chemicals that interfere with cell division, attacking cancer at its most vulnerable moment—when it's copying its DNA and splitting into two cells. Different chemotherapy drugs target different stages of this process: some cross-link DNA strands so they cannot separate for copying, others masquerade as building blocks for DNA or RNA but cause errors when incorporated, and still others prevent the formation of the mitotic spindle that pulls chromosomes apart during division. Because cancer cells divide far more frequently than most normal cells, they encounter these chemical traps more often and accumulate lethal damage faster.

The systemic nature of chemotherapy is both its strength and weakness. Unlike surgery or radiation that treat specific locations, chemotherapy travels through the bloodstream to reach cancer cells wherever they hide in the body, making it essential for metastatic disease or cancers of the blood and lymph system. This whole-body exposure also explains why chemotherapy causes such severe side effects—it inevitably poisons the body's own rapidly-dividing healthy cells in hair follicles, intestinal lining, and bone marrow, causing hair loss, nausea, and immune suppression.

Oncologists typically administer chemotherapy in cycles, giving drugs in pulses followed by recovery periods. This cycling allows normal tissues time to regenerate between treatments while maintaining continuous pressure on the cancer. Drug combinations are common because cancer cells may develop resistance to individual agents through mutations, but facing multiple chemical attacks simultaneously makes escape less likely. Despite the harsh side effects, chemotherapy remains a cornerstone of cancer treatment because for many cancers, it's the only way to attack disease that has spread beyond a single site.

The immune system normally patrols the body for foreign invaders and damaged cells, but cancer evolves elaborate disguises to evade detection—essentially putting on a molecular costume that says "don't attack me, I belong here." Immunotherapy strips away these disguises or supercharges the immune system's ability to recognize and destroy cancer cells. The approach represents a fundamental shift from poisoning cancer directly to unleashing the body's own surveillance system to do the work.

Checkpoint inhibitors are the most prominent immunotherapy approach, working by removing the brakes on immune cells. Cancer cells often display proteins like PD-L1 that bind to receptors on T cells (the immune system's killer cells) and send "off" signals that prevent attack. Drugs like pembrolizumab block these inhibitory signals, essentially cutting the brake lines and allowing T cells to assault cancer cells they could previously detect but not attack. This explains why immunotherapy can cause autoimmune side effects—removing brakes can lead T cells to attack healthy tissue too.

CAR-T cell therapy takes a more engineered approach by removing a patient's own T cells, genetically reprogramming them in the laboratory to express artificial receptors that recognize specific cancer markers, then infusing billions of these weaponized cells back into the patient. These designer immune cells can hunt down cancer with extraordinary precision and persist for years, providing ongoing surveillance. Other immunotherapy strategies include cancer vaccines that train the immune system to recognize tumor-specific proteins and cytokine therapies that amplify immune responses generally, creating an inflammatory environment hostile to cancer growth.

Targeted therapy exploits specific genetic mutations or molecular abnormalities that drive a particular patient's cancer, attacking those precise vulnerabilities while largely ignoring normal cells. Unlike chemotherapy's scattershot approach of poisoning all dividing cells, targeted drugs are designed to interfere with particular proteins produced by cancer-causing mutations. For example, some lung cancers have mutations in the EGFR gene that cause cells to produce an overactive growth-stimulating protein; drugs like erlotinib are small molecules shaped to fit into and block this specific mutant protein's active site, shutting down the growth signal.

The development of targeted therapies depends on understanding the molecular profile of each individual cancer through genomic testing. Oncologists now routinely sequence tumor DNA to identify "actionable mutations"—genetic alterations for which targeted drugs exist. Chronic myeloid leukemia provides a landmark example: the disease is driven by the BCR-ABL fusion protein, an abnormal enzyme created by a chromosomal rearrangement. Imatinib was designed to fit precisely into this enzyme's ATP-binding pocket, blocking its function and transforming what was once a fatal disease into a manageable chronic condition for many patients.

Targeted therapy has limitations that reflect cancer's adaptability. Because these drugs attack single molecular targets, cancer cells can develop resistance through additional mutations that alter the drug's binding site or activate alternative growth pathways. Oncologists increasingly use combination approaches, attacking multiple targets simultaneously to prevent escape routes, or sequence different targeted drugs as resistance emerges. The specificity of targeted therapy means fewer side effects than traditional chemotherapy, though problems still arise because the targeted proteins often have some function in normal cells, and inhibiting them throughout the body creates its own complications.